share_log

金斯瑞生物科技(01548.HK):欧盟委员会批准CARVYKTI用于复发难治性多发性骨髓瘤患者二线治疗

Kingsley Biotechnology (01548.HK): The European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma

Gelonghui Finance ·  Apr 22 20:31

Gelonghui, April 23 | Kingsley Biotechnology (01548.HK) issued an announcement. On April 22, 2024, Legend Biotech issued a press release announcing that the European Commission (EC) approved CARVYKTI(ciltacabtagene autoleucel, cilta-cel) is used to treat adult patients with recurrent and refractory multiple myeloma who have previously received at least one treatment, including proteasome inhibitors (PI) and immunomodulators (IMID). Patients showed disease progression during the last treatment, and lenalidomide was difficult to treat.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment